Skip to Content
Diagnosed with severe psoriasis? Learn about biologics >>

Erythromycin Pregnancy and Breastfeeding Warnings

Erythromycin is also known as: E-Mycin, E.E.S. Granules, E.E.S.-200, E.E.S.-400, E.E.S.-400 Filmtab, Ery-Tab, EryPed, Eryc, Erythrocin, Erythrocin Lactobionate, Erythrocin Stearate Filmtab, Erythrocot, Ilosone, MY-E, PCE Dispertab, Robimycin, Wyamycin S

Erythromycin Pregnancy Warnings

Erythromycin crosses the placenta in small amounts. In one study of 11 patients who had detectable erythromycin levels in the serum, 4 infants did not have detectable cord concentrations. The cord concentrations in the remaining 7 infants generally ranged from 1% to 6% of that found in maternal serum. A case of left absence-of-tibia syndrome was reported in an infant whose mother had received erythromycin, ethisterone, and ethinyl estradiol at approximately 4 weeks gestation. Erythromycin has been used prior to delivery in women colonized with group B beta-hemolytic streptococcus to reduce infant colonization. No adverse events in the infants have been reported. Erythromycin has also been used to treat genital Mycoplasma infection during the first trimester without evidence of fetal adverse effects. Pregnant women receiving erythromycin estolate may be more prone to hepatotoxicity. In one study of women receiving erythromycin estolate between the 22nd and 32nd week of pregnancy, 10% showed abnormal levels of SGOT.

Erythromycin has been assigned to pregnancy category B by the FDA. Animal studies failed to reveal evidence of teratogenicity. There are no controlled data in human pregnancy. The Centers for Disease Control and Prevention considers erythromycin the drug of choice for treatment of Chlamydia infections in pregnant women. However, erythromycin estolate is considered contraindicated because of drug-related hepatotoxicity. Erythromycin should only be given during pregnancy when need has been clearly established.

See references

Erythromycin Breastfeeding Warnings

Erythromycin is excreted into human milk in small amounts. Erythromycin is considered compatible with breast-feeding by the American Academy of Pediatrics.

See references

References for pregnancy information

  1. Mahon BE, Rosenman MB, Kleiman MB "Maternal and infant use of erythromycin and other macrolide antibiotics as risk factors for infantile hypertrophic pyloric stenosis." J Pediatr 139 (2001): 380-4
  2. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control "1993 Sexually Transmitted Diseases Treatment Guidelines." MMWR Morb Mortal Wkly Rep 42 (1993): 27-46
  3. "Sexually transmitted diseases treatment guidelines 2002." MMWR Morb Mortal Wkly Rep 51(RR-6) (2002): 1-77
  4. Philipson A, Sabath LD, Charles D "Transplacental passage of erythromycin and clindamycin." N Engl J Med 288 (1973): 1219-21
  5. Merenstein GB, Todd WA, Brown G, Yost CC, Luzier T "Group B beta-hemolytic streptococcus: randomized controlled treatment study at term." Obstet Gynecol 55 (1980): 315-8
  6. Easmon CS, Hastings MJ, Deeley J, Bloxham B, Rivers RP, Marwood R "The effect of intrapartum chemoprophylaxis on the vertical transmission of group B streptococci." Br J Obstet Gynaecol 90 (1983): 633-5
  7. Louik C, Werler MM, Mitchell AA "Erythromycin use during pregnancy in relation to pyloric stenosis." Am J Obstet Gynecol 186 (2002): 288-90
  8. "Product Information. ERYC (erythromycin)." Parke-Davis, Morris Plains, NJ.
  9. Hussain N, Herson VC "Erythromycin use during pregnancy in relation to pyloric stenosis." Am J Obstet Gynecol 187(3 Pt 1) (2002): 821-2
  10. McCormack WM, George H, Donner A, et al. "Hepatotoxicity of erythromycin estolate during pregnancy." Antimicrob Agents Chemother 12 (1977): 630-5
  11. Quinn PA, Shewchuk AB, Shuber J, et al. "Eficacy of antibiotic therapy in preventing spontaneous pregnancy loss among couples colonized with genital mycoplasms." Am J Obstet Gynecol 145 (1983): 239-44
  12. Jaffe P, Liberman MM, McFadyen I, Valman HB "Incidence of congenital limb-reduction deformities." Lancet 1 (1975): 526-7
  13. Kiefer L, Rubin A, McCoy JB, Foltz EL "The placental transfer of erythromycin." Am J Obstet Gynecol 69 (1955): 174-7

References for breastfeeding information

  1. "Product Information. ERYC (erythromycin)." Parke-Davis, Morris Plains, NJ.
  2. Roberts RJ, Blumer JL, Gorman RL, et al "American Academy of Pediatrics Committee on Drugs: Transfer of drugs and other chemicals into human milk." Pediatrics 84 (1989): 924-36
  3. Committee on Drugs, 1992 to 1993 "The transfer of drugs and other chemicals into human milk." Pediatrics 93 (1994): 137-50

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.